As of February, 20 G1 Therapeutics, Inc. (GTHX) EPS Estimated At $-0.58

G1 Therapeutics, Inc. (NASDAQ:GTHX)’s earnings release is anticipated by WallStreet on February, 20, as reported by Faxor. Analysts forecast $-0.58 EPS, which is $0.02 up or 3.33 % from 2018’s $-0.6 EPS. Last quarter $-0.59 EPS was reported. Analysts forecasts -1.69 % EPS growth this quarter. GTHX touched $21.08 during the last trading session after $0.3 change.G1 Therapeutics, Inc. has volume of 147,032 shares. Since February 14, 2018 GTHX has risen 68.97% and is uptrending. GTHX outperformed the S&P 500 by 68.97%.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States.The company has $783.86 million market cap. It is developing trilaciclib, an intravenous cyclin-dependent kinases 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage.Last it reported negative earnings. The firm has a clinical trial collaboration agreement with AstraZeneca to evaluate AstraZeneca??s epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Tagrisso (osimertinib) in combination with oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer; and a research partnership GeneCentric Therapeutics, Inc. to identify subtypes of lung cancer where the compound is likely to be efficacious.

For more G1 Therapeutics, Inc. (NASDAQ:GTHX) news posted recently go to:,,, or The titles are as follows: “UBS likes Lilly in premarket analyst action – Seeking Alpha” posted on January 23, 2019, “G1 Therapeutics to Present at Investor Conferences in November 2018 – GlobeNewswire” on November 06, 2018, “G1 Therapeutics down 18% on mixed results from mid-stage study of trilaciclib – Seeking Alpha” with a publish date: November 27, 2018, “G1 Therapeutics’ trilaciclib fails to beat placebo in mid-stage lung cancer study; shares down 24% after hours – Seeking Alpha” and the last “Is Honeywell a Good Value Stock for 2019? – Nasdaq” with publication date: February 09, 2019.

G1 Therapeutics, Inc. (NASDAQ:GTHX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.